文献速递临床试验与 GCP流行病学与生物统计

二价呼吸道合胞病毒预融合F蛋白疫苗预防老年人心血管住院:DAN-RSV试验的预设分析

Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial.
PubMed 文献 · JAMA · 2025-01-01

DAN-RSV试验的预设二次分析在丹麦2024-2025年冬季纳入131 276名60岁及以上成人,按1:1随机接受RSVpreF疫苗或不接种。RSVpreF组全因心肺住院发生率低于对照组(26.3 vs 29.2例/1000人年),疫苗有效性9.9%(95%CI 0.3%-18.7%;P=0.04);全因心血管住院疫苗有效性7.4%(95%CI -5.5%至18.8%;P=0.24),未达统计学显著。

要点

  • 60岁及以上成人接种RSVpreF后全因心肺住院发生率低于不接种组,疫苗有效性9.9%(95%CI 0.3%-18.7%;P=0.04)。
  • 全因心血管住院发生率RSVpreF组16.4 vs 对照组17.7例/1000人年,疫苗有效性7.4%(95%CI -5.5%至18.8%;P=0.24),未达统计学显著。
  • 基线有无心血管疾病对心肺住院疫苗有效性的交互作用无统计学意义(P=0.27)。

核心结论

  • 在60岁及以上成人中,RSVpreF组全因心肺住院显著低于不接种组。
  • 作者认为研究结果提示RSV免疫可能带来下游心肺获益,但对全因心血管住院的影响未达统计学显著。

研究设计与样本

  • DAN-RSV试验的预设二次分析;DAN-RSV为在丹麦2024-2025年冬季开展的实用性、开放标签、个体随机临床试验。
  • 首例参与者于2024年11月18日入组;60岁及以上成人无论合并症状态均可入选。
  • 参与者按1:1随机接受RSVpreF(n=65 642)或不接种疫苗(n=65 634)。
  • 共纳入131 276人,平均年龄69.4岁(SD 6.5),男性占50.3%,基线有心血管疾病者28 662人(21.8%)。
  • 结局从预约研究访视后14天评估至2025年5月31日;疫苗有效性按1-发病率比计算,以百分比表示。

主要发现

  • 全因心肺住院发生率RSVpreF组26.3 vs 对照组29.2例/1000人年,绝对率降低2.90(95%CI 0.10-5.71)/1000人年,疫苗有效性9.9%(95%CI 0.3%-18.7%;P=0.04)。
  • 基线心血管疾病状态交互作用无统计学意义:基线有心血管疾病者疫苗有效性5.0%(95%CI -11.2%至16.7%),无心血管疾病者15.2%(95%CI 2.2%-27.1%),交互作用P=0.27。
  • 全因心血管住院发生率RSVpreF组16.4 vs 对照组17.7例/1000人年,疫苗有效性7.4%(95%CI -5.5%至18.8%;P=0.24)。
  • 卒中发生率RSVpreF组3.0 vs 对照组3.8例/1000人年,疫苗有效性19.4%(95%CI -8.6%至40.4%;P=0.14)。
  • 心肌梗死、心力衰竭住院和心房颤动方面,组间差异均无统计学意义。

关键数值与推荐

  • 全因心肺住院为预设次要结局;全因心血管疾病、心力衰竭、心肌梗死、卒中和心房颤动住院为预设探索性结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Respiratory syncytial virus (RSV) infection is linked to elevated cardiovascular risk, particularly in individuals with preexisting cardiovascular disease (CVD). A bivalent RSV prefusion F protein (RSVpreF) vaccine was recently approved for preventing RSV-related lower respiratory tract illness, but its effectiveness against cardiovascular outcomes has not been evaluated in a randomized trial. OBJECTIVE: To investigate the vaccine effectiveness of RSVpreF compared with no vaccine against cardiovascular outcomes among adults aged 60 years or older. DESIGN, SETTING, AND PARTICIPANTS: Prespecified secondary analysis of the DAN-RSV trial, a pragmatic, open-label, individually randomized clinical trial conducted in Denmark during the 2024-2025 winter season. The first participant was enrolled on November 18, 2024. Adults aged 60 years or older were eligible for inclusion regardless of comorbidity status. INTERVENTIONS: Participants were randomized 1:1 to receive RSVpreF (n = 65 642) or no vaccine (n = 65 634). MAIN OUTCOMES AND MEASURES: Hospitalization for any cardiorespiratory disease was a prespecified secondary outcome, and hospitalizations for any CVD, heart failure, myocardial infarction, stroke, and atrial fibrillation were prespecified exploratory outcomes. Outcomes were assessed from 14 days after booked study visit through May 31, 2025. Vaccine effectiveness was calculated as 1 - incidence rate ratio, expressed as a percentage. RESULTS: Of 131 276 participants included (mean age, 69.4 [SD, 6.5] years; 50.3% male), 28 662 (21.8%) had preexisting CVD. All-cause cardiorespiratory hospitalization incidence was lower in the RSVpreF group compared with the control group (26.3 vs 29.2 events per 1000 participant-years [PY]; absolute rate reduction, 2.90 [95% CI, 0.10-5.71] per 1000 PY; vaccine effectiveness, 9.9% [95% CI, 0.3%-18.7%]; P = .04). There was no significant interaction by baseline CVD status (CVD at baseline: vaccine effectiveness, 5.0% [95% CI, -11.2% to 16.7%]; no CVD at baseline: vaccine effectiveness, 15.2% [95% CI, 2.2%-27.1%]; P = .27 for interaction). For the RSVpreF group vs control group, respectively, incidence rates of all-cause cardiovascular hospitalization were 16.4 vs 17.7 events per 1000 PY (vaccine effectiveness, 7.4% [95% CI, -5.5% to 18.8%]; P = .24), and incidence rates of stroke were 3.0 vs 3.8 events per 1000 PY (vaccine effectiveness, 19.4% [95% CI, -8.6% to 40.4%]; P = .14). There were also no statistically significant between-group differences for myocardial infarction, heart failure hospitalization, and atrial fibrillation. CONCLUSIONS AND RELEVANCE: In adults aged 60 years or older, all-cause cardiorespiratory hospitalization was significantly lower with RSVpreF than with no vaccine. The findings suggest potential downstream cardiorespiratory benefits of RSV immunization, although the effect on all-cause cardiovascular hospitalization was not statistically significant. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06684743.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lassen MCH, Johansen ND, Christensen SH, et al. Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV Trial. JAMA. 2025. PMID: 40884493. doi:10.1001/jama.2025.15405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。